Oasmia Gets FDA Approval for Paccal Vet in Two Canine Cancers

Oasmia Pharmaceutical AB (OASM) got conditional approval for Paccal Vet from the U.S. Food and Drug Administration for the treatment of two canine cancers.

The FDA approved the drug for dogs with squamous cell skin cancer and mammary carcinomas, providing a treatment option for indications where there are currently no effective systematic treatment choices, the company said in a statement today.

Paccal Vet is one of two dog cancer drug candidates the company is developing under a license and distribution agreement with Abbott Laboratories. (ABT) Uppsala, Sweden-based Oasmia’s animal health program focuses on the two most common indications, mastocytoma and lymphoma, which make up about half of all cancers in dogs.

“Ever since we started this project 15 years ago, we have waited for the day when we could have a product on the market,” Oasmia Chief Executive Officer Julian Aleksov said in a text message. “There is a large and rapidly growing market for effective drugs that can treat cancer in dogs, and we believe Paccal Vet, being the first cytostatic drug specifically made for dogs, has a great potential to become the standard treatment.”

Shares in the Swedish drugmaker have advanced 25 percent this year, giving the company a market value of 2 billion kronor ($307 million).

To contact the reporter on this story: Kim McLaughlin in Stockholm at kmclaughlin6@bloomberg.net

To contact the editors responsible for this story: David Risser at drisser@bloomberg.net Alastair Reed, Niklas Magnusson

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.